NCT06447415View on ClinicalTrials.gov

Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 6, 2024

Primary Completion Date

March 18, 2025

Study Completion Date

June 11, 2025

Conditions

Acute Ischemic Stroke

Interventions

DRUG

HRS-7450

HRS-7450 Injection

DRUG

0.9% sodium chloride injection

Trial Locations (1)

510062

The First Affiliated Hospital of Sun Yat sen University, Guangzhou

All Listed Sponsors

lead

Fujian Shengdi Pharmaceutical Co., Ltd.

INDUSTRY

NCT06447415 - Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke: a Multi-center, Randomized, Double-blind, Double-dummy, Placebo-controlled Clinical Trial | Biotech Hunter | Biotech Hunter